Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase–mediated (LPL-mediated) lipolysis of VLDL TGs may also be reduced in T2DM if the level of LPL is decreased and/or the level of plasma apoC-III, an inhibitor of LPL-mediated lipolysis, is increased. We studied the effects of pioglitazone (Pio), a PPARγ agonist that improves insulin sensitivity, on lipoprotein metabolism in patients with T2DM. Pio treatment reduced TG levels by increasing the fractional clearance rate (FCR) of VLDL TGs from the circulation, without changing direct removal of VLDL particles. This indicated increased lipolysis of VLDL TGs during Pio treatment, a mechanism supported by our finding of increased plasma LPL mass and decreased levels of plasma apoC-III. Lower apoC-III levels were due to reduced apoC-III PRs. We saw no effects of Pio on the PR of either VLDL TG or VLDL apoB. Thus, Pio, a PPARγ agonist, reduced VLDL TG levels by increasing LPL mass and inhibiting apoC-III PR. These 2 changes were associated with an increased FCR of VLDL TGs, almost certainly due to increased LPL-mediated lipolysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 2×
“gene expression is suppressed by PPARα agonists (67), possibly via direct binding of activated PPARα, in a nonproductive manner, to a hepatocyte nuclear factor-4 site in the apoC-III promoter (68, 69).”
BackgroundInsulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Self-citationSchoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173 · cited 1×
“LPL is a PPARγ-responsive gene (56), and the PPARγ agonist troglitazone has been demonstrated to increase postheparin plasma LPL activity (57) and both preheparin (58) and postheparin (59) LPL mass in subjects with diabetes and/or insulin resistance.”
BackgroundAn Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921 · cited 2×
“ApoA-V is a recently identified apolipoprotein that appears to play an important role in TG metabolism (21), and several studies have shown that polymorphisms in the apoA-V gene are associated with hypertriglyceridemia (21, 78).”
BackgroundSHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855 · cited 1×
“Recent studies in rodents suggest that insulin can stimulate lipogenesis by increasing SREBP1c gene expression (44, 45) via an IRS/PI3K-independent pathway (46), although there are now conflicting data regarding this issue (47–49).”
ResultShimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13656 · Cited by 793 · cited 2×
“Recent studies in rodents suggest that insulin can stimulate lipogenesis by increasing SREBP1c gene expression (44, 45) via an IRS/PI3K-independent pathway (46), although there are now conflicting data regarding this issue (47–49).”
BackgroundResultLife without white fat: a transgenic mouse
Moitra, J., Mason, M. M., Olive, M., Krylov, D., Gavrilova, O., Marcus-Samuels, B., Feigenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., et al. (1998) · Genes & Development · doi:10.1101/gad.12.20.3168 · Cited by 782 · cited 1×
“Studies in ob/ob and db/db mice (86), A-ZIP total lipodystrophic mice (87), and brown adipose tissue–deficient (BATless) (88) mice, all models of insulin resistance, have demonstrated increased hepatic expression of PPARγ and increased hepatic lipogenesis.”
BackgroundMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726 · cited 1×
“Troglitazone (12), Rosi (53), and Pio (13) have all been shown to have modest effects on the ability of insulin to suppress hepatic glucose production, but effects of TZDs on hepatic lipid metabolism are less well described.”
BackgroundGavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
Vidal-Puig, A., Jimenez-Liñan, M., Lowell, B. B., Hamann, A., Hu, E., Spiegelman, B., Flier, J. S., & Moller, D. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118703 · Cited by 655 · cited 1×
“Studies in ob/ob and db/db mice (86), A-ZIP total lipodystrophic mice (87), and brown adipose tissue–deficient (BATless) (88) mice, all models of insulin resistance, have demonstrated increased hepatic expression of PPARγ and increased hepatic lipogenesis.”
BackgroundMayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Matsusue, K., Haluzik, M., Lambert, G., Yim, S.-H., Gavrilova, O., Ward, J. M., Brewer, B., Reitman, M. L., & Gonzalez, F. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317223 · Cited by 585
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Lewis, G. F., Uffelman, K. D., Szeto, L. W., Weller, B., & Steiner, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117633 · Cited by 502 · cited 1×
“demonstrated that in healthy humans, increasing plasma FA flux by infusion of a TG emulsion and heparin increased VLDL secretion from the liver (34).”
BackgroundInhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Virgil Brown, W., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 491 · cited 1×
“ApoC-III, a major component of VLDL, inhibits the activity of LPL in vitro (64) and in vivo (20), and increased expression of apoC-III in a transgenic mouse was associated with hypertriglyceridemia (65).”
BackgroundFisher, E. A., & Ginsberg, H. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100068200 · Cited by 460 · cited 1×
“Although very low levels of LPL activity, in association with marked hypertriglyceridemia and hyperchylomicronemia, have been observed in decompensated patients with T2DM (23), the prevailing view is that moderate hypertriglyceridemia in the typical patient with T2DM results from increased assembly and secretion of TG…”
BackgroundSelf-citationAalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450 · cited 1×
“ApoC-III, a major component of VLDL, inhibits the activity of LPL in vitro (64) and in vivo (20), and increased expression of apoC-III in a transgenic mouse was associated with hypertriglyceridemia (65).”
BackgroundSelf-citationGinsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Self-citationGeorge Lyman Duff Memorial Lecture. Atherogenesis in diabetes.
Bierman, E. L. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.6.647 · Cited by 413
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y.-H., Ricote, M., Glass, C. K., Brewer, H. B., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2607-2619.2002 · Cited by 368 · cited 3×
“Finally, it has been suggested that PPARγ signaling may play a role in stimulating expression of the gene encoding ABCA1 (81), which could increase the flux of cholesterol from cells onto nascent apoA-I (82).”
BackgroundMeasurement of de novo hepatic lipogenesis in humans using stable isotopes.
Hellerstein, M. K., Christiansen, M., Kaempfer, S., Kletke, C., Wu, K., Reid, J. S., Mulligan, K., Hellerstein, N. S., & Shackleton, C. H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115206 · Cited by 362
Bajaj, M., Suraamornkul, S., Piper, P., Hardies, L. J., Glass, L., Cersosimo, E., Pratipanawatr, T., Miyazaki, Y., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031315 · Cited by 358 · cited 2×
“We realize that studies demonstrating reductions in hepatic fat (measured by magnetic resonance spectroscopy) in patients with T2DM after treatment with either Rosi (14) or Pio (83) argue against our proposal, but we would note that in both published studies (14, 83), hepatic TG mass after TZD treatment remained signi…”
BackgroundResultChao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., & Reitman, M. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11245 · Cited by 356
Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance
Taghibiglou, C., Carpentier, A., Van Iderstine, S. C., Chen, B., Rudy, D., Aiton, A., Lewis, G. F., & Adeli, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8416 · Cited by 347 · cited 1×
“Insulin-mediated degradation of nascent apoB appears to be a second important regulator of the assembly and secretion of VLDL from healthy livers (35, 36), and defects in this pathway, leading to increased apoB secretion, have been demonstrated in insulin-resistant rodent models (37, 38)”
BackgroundMode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339 · cited 1×
“gene expression is suppressed by PPARα agonists (67), possibly via direct binding of activated PPARα, in a nonproductive manner, to a hepatocyte nuclear factor-4 site in the apoC-III promoter (68, 69).”
BackgroundHavel, R. J., Kane, J. P., Balasse, E. O., Segel, N., & Basso, L. V. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106422 · Cited by 336 · cited 1×
“Pio treatment also lowered plasma FA levels, a good indication that FA flux to the liver fell (85).”
BackgroundLewis, G. F., Uffelman, K. D., Szeto, L. W., & Steiner, G. (1993) · Diabetes · doi:10.2337/diab.42.6.833 · Cited by 324
CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ
Herzig, S., Hedrick, S., Morantte, I., Koo, S.-H., Galimi, F., & Montminy, M. (2003) · Nature · doi:10.1038/nature02110 · Cited by 321
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319
Maeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3868 · Cited by 313 · cited 2×
“Effects of PPARγ agonists on apoC-III gene expression have not been reported previously, although both Pio and Rosi have been shown to bind to and stimulate a PPARα reporter gene in transactivation assays (72).”
BackgroundFoxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309 · cited 1×
“(73) indicated that insulin’s ability to inhibit apoC-III gene expression was via inhibition of Foxo1 binding to the putative insulin response element of apoC-III (74, 75) in hepatocytes.”
BackgroundMemon, R. A., Tecott, L. H., Nonogaki, K., Beigneux, A., Moser, A. H., Grunfeld, C., & Feingold, K. R. (2000) · Endocrinology · doi:10.1210/endo.141.11.7771 · Cited by 302
Maggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286 · cited 1×
“Troglitazone (12), Rosi (53), and Pio (13) have all been shown to have modest effects on the ability of insulin to suppress hepatic glucose production, but effects of TZDs on hepatic lipid metabolism are less well described.”
BackgroundLi, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278 · cited 1×
“(73) indicated that insulin’s ability to inhibit apoC-III gene expression was via inhibition of Foxo1 binding to the putative insulin response element of apoC-III (74, 75) in hepatocytes.”
BackgroundLipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis
Ginsberg, H. N. (1991) · Diabetes Care · doi:10.2337/diacare.14.9.839 · Cited by 277 · cited 3×
“Although very low levels of LPL activity, in association with marked hypertriglyceridemia and hyperchylomicronemia, have been observed in decompensated patients with T2DM (23), the prevailing view is that moderate hypertriglyceridemia in the typical patient with T2DM results from increased assembly and secretion of TG…”
BackgroundSelf-citationMiyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetologia · doi:10.1007/s001250100031 · Cited by 274 · cited 8×
“Troglitazone (12), Rosi (53), and Pio (13) have all been shown to have modest effects on the ability of insulin to suppress hepatic glucose production, but effects of TZDs on hepatic lipid metabolism are less well described.”
BackgroundInfluentialKakuma, T., Lee, Y., Higa, M., Wang, Z.-W., Pan, W., Shimomura, I., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8536 · Cited by 261 · cited 1×
“We also expected that Pio treatment would lower plasma TG levels by decreasing the assembly and secretion of both VLDL TGs and VLDL apoB by its ability to: (a) improve adipose tissue sensitivity to insulin, thereby reducing FA flux from adipose tissue to the liver (15, 52, 53); (b) reduce plasma insulin levels, thereb…”
BackgroundFoxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419992 · Cited by 260
JANUS, E. D., NICOLL, A. M., TURNER, P. R., MAGILL, P., & LEWIS, B. (1980) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1980.tb02076.x · Cited by 250
Diabetic Lipemia: A Form of Acquired Fat-Induced Lipemia
Bagdade, J. D., Porte, D., & Bierman, E. L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702232760802 · Cited by 248 · cited 1×
“Although very low levels of LPL activity, in association with marked hypertriglyceridemia and hyperchylomicronemia, have been observed in decompensated patients with T2DM (23), the prevailing view is that moderate hypertriglyceridemia in the typical patient with T2DM results from increased assembly and secretion of TG…”
BackgroundAdiponectin: Systemic contributor to insulin sensitivity
Pajvani, U. B., & Scherer, P. E. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0065-2 · Cited by 244 · cited 1×
“Pio treatment improved insulin sensitivity, as reflected in the parallel falls of plasma insulin and glucose levels, and the dramatic rise in adiponectin levels (83, 84).”
BackgroundFreed, M. I., Ratner, R., Marcovina, S. M., Kreider, M. M., Biswas, N., Cohen, B. R., & Brunzell, J. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02659-0 · Cited by 238
Hanefeld, M., Brunetti, P., Schernthaner, G. H., Matthews, D. R., Charbonnel, B. H., & on behalf of the QUARTET Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.1.141 · Cited by 230 · cited 3×
“TZDs appear to increase mean LDL size (17).”
ResultInsulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion
Sparks, J. D., & Sparks, C. E. (1994) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)90088-4 · Cited by 222 · cited 2×
“Insulin-mediated degradation of nascent apoB appears to be a second important regulator of the assembly and secretion of VLDL from healthy livers (35, 36), and defects in this pathway, leading to increased apoB secretion, have been demonstrated in insulin-resistant rodent models (37, 38)”
BackgroundAarsland, A., Chinkes, D., & Wolfe, R. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119005 · Cited by 212
Arad, Y., Ramakrishnan, R., & Ginsberg, H. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42825-1 · Cited by 212
Self-citationThe Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis
Ginsberg, H. N., & Huang, L.-S. (2000) · European Journal of Cardiovascular Risk · doi:10.1177/204748730000700505 · Cited by 209 · cited 1×
“Discussion Hypertriglyceridemia is a central component of diabetic dyslipidemia (4, 5) and is also an integral pathophysiologic component of the insulin resistance syndrome (7, 22) (often referred to as syn-”
BackgroundSelf-citationVu-Dac, N., Gervois, P., Jakel, H., Nowak, M., Baugé, E., Dehondt, H., Staels, B., Pennacchio, L. A., Rubin, E. M., Fruchart-Najib, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212191200 · Cited by 206 · cited 2×
“ApoA-V is regulated by PPARα (79), and the lack of effect of Pio on apoA-V levels argues against any significant PPARα activity of Pio in our patients.”
BackgroundSelf-citationCastro Cabezas, M., de Bruin, T. W., de Valk, H. W., Shoulders, C. C., Jansen, H., & Willem Erkelens, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116544 · Cited by 200
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
Fruchart-Najib, J., Baugé, E., Niculescu, L.-S., Pham, T., Thomas, B., Rommens, C., Majd, Z., Brewer, B., Pennacchio, L. A., & Fruchart, J.-C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.003 · Cited by 198 · cited 1×
“body raised against a human apoA-V synthetic peptide (94).”
BackgroundSelf-citationBogacka, I., Xie, H., Bray, G. A., & Smith, S. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1660 · Cited by 197 · cited 1×
“A recent study demonstrated increases in adipose tissue LPL mRNA levels in patients with T2DM treated with Pio (63).”
BackgroundMatsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Tomita, S., Sekiya, M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.3.560 · Cited by 197
Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 184
Role of insulin in regulation of lipoprotein metabolism in diabetes
Reaven, G. M., & Chen, Y. I. (1988) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610040703 · Cited by 179
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170 · cited 1×
“This schema is consistent with recent studies demonstrating a correlation between insulin resistance and apoC-III production in humans (76).”
ResultSelf-citationOno, H., Shimano, H., Katagiri, H., Yahagi, N., Sakoda, H., Onishi, Y., Anai, M., Ogihara, T., Fujishiro, M., Viana, A. Y. I., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.12.2905 · Cited by 169
Boyle, P. J., King, A. B., Olansky, L., Marchetti, A., Lau, H., Magar, R., & Martin, J. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85040-8 · Cited by 161
Bajaj, M., Suraamornkul, S., Hardies, L. J., Pratipanawatr, T., & DeFronzo, R. A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802625 · Cited by 159 · cited 1×
“More importantly, these data suggest that Pio, by increasing hepatic insulin sensitivity (77), could reduce expression of the apoC-III gene.”
BackgroundHaemmerle, G., Zimmermann, R., Strauss, J. G., Kratky, D., Riederer, M., Knipping, G., & Zechner, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108640200 · Cited by 156 · cited 1×
“Indeed, mice lacking hormone-sensitive lipase have reduced plasma levels of FAs and reduced rates of TG secretion from the liver (32).”
BackgroundDyslipidemia of the metabolic syndrome
Ruotolo, G., & Howard, B. V. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0113-6 · Cited by 155 · cited 1×
“Discussion Hypertriglyceridemia is a central component of diabetic dyslipidemia (4, 5) and is also an integral pathophysiologic component of the insulin resistance syndrome (7, 22) (often referred to as syn-”
BackgroundPEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Cited by 154
Chan, D. C., Watts, G. F., Redgrave, T. G., Mori, T. A., & Barrett, P. H. R. (2002) · Metabolism · doi:10.1053/meta.2002.33339 · Cited by 149 · cited 1×
“On the other hand, overproduction of apoB-containing lipoproteins, including VLDL, has been demonstrated (26, 27) in several in vivo kinetic studies of patients with insulin resistance with or without T2DM.”
BackgroundKesäniemi, Y. A., Beltz, W. F., & Grundy, S. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112010 · Cited by 139 · cited 1×
“Indeed, consistent with published data from studies of normal subjects in several laboratories (50, 51), including our own (20), that is what we found.”
ResultBorradaile, N. M., de Dreu, L. E., & Huff, M. W. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2554 · Cited by 135
Raspé, E., Duez, H., Gervois, P., Fiévet, C., Fruchart, J.-C., Besnard, S., Mariani, J., Tedgui, A., & Staels, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004982200 · Cited by 134 · cited 1×
“PPARα agonists may also suppress apoC-III gene expression indirectly through Rev-erbα antagonism of retinoic acid–related orphan receptor α (RORα), a transcriptional activator of apoC-III (68, 70).”
BackgroundLaws, A., Hoen, H. M., Selby, J. V., Saad, M. F., Haffner, S. M., & Howard, B. V. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.1.64 · Cited by 128
Auwerx, J. H. (2002) · Cited by 127
Ginsberg, H. N., Le, N. A., & Gibson, J. C. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111739 · Cited by 124
Self-citationDiraison, F., & Beylot, M. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.274.2.e321 · Cited by 122
Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM
Cummings, M. H., Watts, G. F., Umpleby, A. M., Hennessy, T. R., Naoumova, R. P., Slavin, B. M., Thompson, G. R., & S�nksen, P. H. (1995) · Diabetologia · doi:10.1007/bf00400586 · Cited by 121 · cited 1×
“On the other hand, overproduction of apoB-containing lipoproteins, including VLDL, has been demonstrated (26, 27) in several in vivo kinetic studies of patients with insulin resistance with or without T2DM.”
BackgroundEffect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes
Boden, G. H., Cheung, P., Mozzoli, M. A., & Fried, S. K. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00055-6 · Cited by 121 · cited 1×
“We also expected that Pio treatment would lower plasma TG levels by decreasing the assembly and secretion of both VLDL TGs and VLDL apoB by its ability to: (a) improve adipose tissue sensitivity to insulin, thereby reducing FA flux from adipose tissue to the liver (15, 52, 53); (b) reduce plasma insulin levels, thereb…”
BackgroundDissociation of apoprotein B and triglyceride production in very-low-density lipoproteins
Melish, J., Le, N. A., Ginsberg, H., Steinberg, D., & Brown, W. V. (1980) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1980.239.5.e354 · Cited by 121
Self-citationAdiels, M., Packard, C., Caslake, M. J., Stewart, P., Soro, A., Westerbacka, J., Wennberg, B., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400108-jlr200 · Cited by 117
Peterson, J., Fujimoto, W., & Brunzell, J. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40768-0 · Cited by 116
Yki-Järvinen, H., & Taskinen, M.-R. (1988) · Diabetes · doi:10.2337/diab.37.9.1271 · Cited by 112
Ayyobi, A. F., & Brunzell, J. D. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00613-1 · Cited by 106
Mar, R., Pajukanta, P., Allayee, H., Groenendijk, M., Dallinga-Thie, G., Krauss, R. M., Sinsheimer, J. S., Cantor, R. M., de Bruin, T. W. A., & Lusis, A. J. (2004) · Circulation Research · doi:10.1161/01.res.0000124922.61830.f0 · Cited by 101 · cited 1×
“ApoA-V is a recently identified apolipoprotein that appears to play an important role in TG metabolism (21), and several studies have shown that polymorphisms in the apoA-V gene are associated with hypertriglyceridemia (21, 78).”
BackgroundCarpentier, A., Taghibiglou, C., Leung, N., Szeto, L., Van Iderstine, S. C., Uffelman, K. D., Buckingham, R., Adeli, K., & Lewis, G. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204568200 · Cited by 97 · cited 1×
“We also expected that Pio treatment would lower plasma TG levels by decreasing the assembly and secretion of both VLDL TGs and VLDL apoB by its ability to: (a) improve adipose tissue sensitivity to insulin, thereby reducing FA flux from adipose tissue to the liver (15, 52, 53); (b) reduce plasma insulin levels, thereb…”
BackgroundSPARKS, J. D., PHUNG, T. L., BOLOGNINO, M., & SPARKS, C. E. (1996) · Biochemical Journal · doi:10.1042/bj3130567 · Cited by 96 · cited 2×
“Insulin-mediated degradation of nascent apoB appears to be a second important regulator of the assembly and secretion of VLDL from healthy livers (35, 36), and defects in this pathway, leading to increased apoB secretion, have been demonstrated in insulin-resistant rodent models (37, 38)”
BackgroundZhang, Y.-L., Hernandez-Ono, A., Ko, C., Yasunaga, K., Huang, L.-S., & Ginsberg, H. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400220200 · Cited by 94 · cited 1×
“Further, we have shown that intravenous infusion of albumin-bound FAs increases secretion of VLDL from livers of normal mice (33).”
BackgroundSelf-citationMalmendier, C. L., Lontie, J., Delcroix, C., Dubois, D. Y., Magot, T., & Roy, L. D. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90075-0 · Cited by 94 · cited 1×
“reported that fenofibrate, a PPARα agonist, lowered apoC-III production in humans (71).”
BackgroundOrphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter
Coste, H., & Rodrı́guez, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203421200 · Cited by 83 · cited 2×
“PPARα agonists may also suppress apoC-III gene expression indirectly through Rev-erbα antagonism of retinoic acid–related orphan receptor α (RORα), a transcriptional activator of apoC-III (68, 70).”
BackgroundLewis, G. F., Uffelman, K. D., Szeto, L., et al. (1993) · Diabetes · doi:10.2337/diabetes.42.6.833 · Cited by 82
Argmann, C. A., Sawyez, C. G., McNeil, C. J., Hegele, R. A., & Huff, M. W. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000058860.62870.6e · Cited by 74 · cited 1×
“Finally, it has been suggested that PPARγ signaling may play a role in stimulating expression of the gene encoding ABCA1 (81), which could increase the flux of cholesterol from cells onto nascent apoA-I (82).”
BackgroundGinsberg, H., Plutzky, J., & Sobel, B. E. (1999) · European Journal of Cardiovascular Risk · doi:10.1177/204748739900600512 · Cited by 69 · cited 1×
“Because they act to improve insulin sensitivity in muscle, liver, and fat (12–15), they may be active against many of the nonglucose abnormalities present in patients with T2DM (16).”
BackgroundSelf-citationThe effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum
Shirai, K., Itoh, Y., Sasaki, H., Totsuka, M., Murano, T., Watanabe, H., & Miyashita, Y. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00063-7 · Cited by 67 · cited 1×
“LPL is a PPARγ-responsive gene (56), and the PPARγ agonist troglitazone has been demonstrated to increase postheparin plasma LPL activity (57) and both preheparin (58) and postheparin (59) LPL mass in subjects with diabetes and/or insulin resistance.”
BackgroundMemon, R. A. (2000) · Endocrinology · doi:10.1210/en.141.11.4021 · Cited by 65
Kageyama, H., Hirano, T., Okada, K., Ebara, T., Kageyama, A., Murakami, T., Shioda, S., & Adachi, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00663-6 · Cited by 63 · cited 1×
“org Volume 115 Number 5 May 2005 1327 and this was accompanied by a reduction in plasma TG levels and increases in postheparin plasma LPL activity (62).”
BackgroundIncreased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat
Elam, M. B., Wilcox, H. G., Cagen, L. M., Deng, X., Raghow, R., Kumar, P., Heimberg, M., & Russell, J. C. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31533-9 · Cited by 62 · cited 2×
“Recent studies in rodents suggest that insulin can stimulate lipogenesis by increasing SREBP1c gene expression (44, 45) via an IRS/PI3K-independent pathway (46), although there are now conflicting data regarding this issue (47–49).”
BackgroundResultAddressing the Insulin Resistance Syndrome A Role for the Thiazolidinediones
Zimmet, P. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00187-1 · Cited by 52
Yki‐Järvinen, H., & Taskinen, M. (1988) · Diabetes · doi:10.2337/diabetes.37.9.1271 · Cited by 52
Kobayashi, J., Saito, K., Fukamachi, I., Taira, K., Takahashi, K., Bujo, H., & Saito, Y. (2001) · Hormone and Metabolic Research · doi:10.1055/s-2001-16230 · Cited by 49 · cited 1×
“Preheparin LPL mass had modest but significant correlations with plasma TG levels in 2 other studies (60, 61).”
BackgroundHoward, B. V., Reitman, J. S., Vasquez, B., & Zech, L. (1983) · Diabetes · doi:10.2337/diab.32.3.271 · Cited by 48
Obese Zucker (fa/fa) Rats Are Resistant to Insulin′s Inhibitory Effect on Hepatic APO B Secretion
Sparks, J. D., & Sparks, C. E. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2681 · Cited by 44 · cited 1×
“Insulin-mediated degradation of nascent apoB appears to be a second important regulator of the assembly and secretion of VLDL from healthy livers (35, 36), and defects in this pathway, leading to increased apoB secretion, have been demonstrated in insulin-resistant rodent models (37, 38)”
BackgroundVery low density lipoprotein metabolism in diabetes mellitus
Ginsberg, H. N. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030209 · Cited by 43 · cited 1×
“Although very low levels of LPL activity, in association with marked hypertriglyceridemia and hyperchylomicronemia, have been observed in decompensated patients with T2DM (23), the prevailing view is that moderate hypertriglyceridemia in the typical patient with T2DM results from increased assembly and secretion of TG…”
BackgroundSelf-citationDifferences in Lipid Profiles of Patients Given Rosiglitazone Followed by Pioglitazone
LaCivita, K. A., & Villarreal, G. E. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001038 · Cited by 43
Sunayama, S., Watanabe, Y., Ohmura, H., Sawano, M., Shimada, K., Mokuno, H., Daida, H., & Yamaguchi, H. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00138-0 · Cited by 40 · cited 1×
“LPL is a PPARγ-responsive gene (56), and the PPARγ agonist troglitazone has been demonstrated to increase postheparin plasma LPL activity (57) and both preheparin (58) and postheparin (59) LPL mass in subjects with diabetes and/or insulin resistance.”
BackgroundBerglund, L., Witztum, J. L., Galeano, N. F., Khouw, A. S., Ginsberg, H. N., & Ramakrishnan, R. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32577-3 · Cited by 36
Self-citationHirano, T., Nishioka, F., & Murakami, T. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.021 · Cited by 34 · cited 1×
“Preheparin LPL mass had modest but significant correlations with plasma TG levels in 2 other studies (60, 61).”
BackgroundThe experimental production of glycogen storage in cultured human fibroblasts
Brown, B. I., & Brown, D. H. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80115-3 · Cited by 32
Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase
Kobayashi, J., Nagashima, I., Hikita, M., Bujo, H., Takahashi, K., OTABE, M., Morisaki, N., & Saito, Y. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00920.x · Cited by 29 · cited 2×
“In the latter study, troglitazone significantly lowered plasma TG levels at the same time (59).”
BackgroundRacette, S. B., Davis, A. O., McGill, J. B., & Klein, S. (2002) · Metabolism · doi:10.1053/meta.2002.29981 · Cited by 29 · cited 1×
“We also expected that Pio treatment would lower plasma TG levels by decreasing the assembly and secretion of both VLDL TGs and VLDL apoB by its ability to: (a) improve adipose tissue sensitivity to insulin, thereby reducing FA flux from adipose tissue to the liver (15, 52, 53); (b) reduce plasma insulin levels, thereb…”
Background[23] Sandwich immunoassay for measurement of human hepatic lipase
Bensadoun, A. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)63025-0 · Cited by 27
Self-citationHoward, B. V., Reitman, J. S., Vasquez, B., et al. (1983) · Diabetes · doi:10.2337/diabetes.32.3.271 · Cited by 18
Ginsberg, H. N., Jacobs, A. K., Le, N., & Sandler, J. M. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110721 · Cited by 17
Self-citation
Research works printed but not linked: 3
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- Diraison, 1998, Am. J. Physiol., 274, E321
- Melish, 1980, Am. J. Physiol., 239, E354
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationAdiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“TZDs decrease adipocyte inflammation and increase secretion of adiponectin, enhance clearance of VLDL triglyceride (Nagashima et al., 2005), improve insulin-mediated suppression of lipolysis (Mayerson et al., 2002), and lower rates of post-prandial fatty acid turnover (Miles et al., 2003).”
Pathophysiology of Diabetic Dyslipidemia
Hirano, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17023 · Cited by 552
Metadata
- Authors
- Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., & Ginsberg, H. N.
- Affiliations
- Columbia University (US)
- Cornell University (US)
- Montreal Clinical Research Institute (CA)
- Corresponding author
- Ginsberg, Henry N.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-04-01
- Volume
- 115
- Issue
- 5
- Pages
- 1323-1332
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1070635
- OpenAlex
- W2132525699
- Cited by
- 201
- References
- 104
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- Takeda Pharmaceuticals North America
- Deutsches Krebsforschungszentrum
- National Institutes of Health (RR-00645)
- National Heart, Lung, and Blood Institute (HL55368)
- National Center for Research Resources (RR 00645, M01RR000645)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, PPARγ agonists, type 2 diabetes, lipoprotein metabolism, VLDL triglycerides, lipoprotein lipase, apolipoprotein C-III, triglyceride clearance, lipolysis, insulin sensitivity
- MeSH terms
- Pioglitazone, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Female, Humans, Hypoglycemic Agents, Insulin, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Triglycerides, Intercellular Signaling Peptides and Proteins, Thiazolidinediones, PPAR gamma, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.